Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03MYI
|
|||
| Drug Name |
PMID28394193-Compound-33
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H39N3O2S
|
|||
| Canonical SMILES |
CCC(C1CCNCC1)C2=C(C3=C(S2)CCN(C3=O)CC4=C(N=C(C=C4C)C)OCC5=CC=CC=C5)C
|
|||
| InChI |
1S/C31H39N3O2S/c1-5-25(24-11-14-32-15-12-24)29-22(4)28-27(37-29)13-16-34(31(28)35)18-26-20(2)17-21(3)33-30(26)36-19-23-9-7-6-8-10-23/h6-10,17,24-25,32H,5,11-16,18-19H2,1-4H3
|
|||
| InChIKey |
SJBPGCIWHCAKKL-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Enhancer of zeste homolog 2 (EZH2) | Target's Patent Info | [1] | |
| KEGG Pathway | MicroRNAs in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | PRC2 methylates histones and DNA | |||
| Oxidative Stress Induced Senescence | ||||
| PKMTs methylate histone lysines | ||||
| WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
| Endoderm Differentiation | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Histone Modifications | ||||
| Cell Differentiation - meta | ||||
| miRs in Muscle Cell Differentiation | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.